EUVIMEDEUVIMED entdecken
Open Access

Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma

Samar Sayedyahossein, Kenneth Huang, Christopher Zhang, Mehdi Karimi, Mehrnoosh Bahmani, Brooke L O'Donnell, Brent Wakefield, Zhigang Li, Danielle Johnston, Stephanie E Leighton, Matthew S Huver, Lina Dagnino und 2 weitere

The FEBS Journal · 2025

DOI: 10.1111/febs.17396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Samar Sayedyahossein und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Melanoma, Nerve Tissue Proteins, Connexins, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we explored the intricate relationship between Pannexin 1 (PANX1) and the Hippo signaling pathway effector, Yes‐associated protein (YAP). Analysis of The Cancer Genome Atlas (TCGA) data revealed a significant positive correlation between PANX1 mRNA and core Hippo components, Yes‐associated protein 1 [YAP], Transcriptional coactivator with PDZ‐binding motif [TAZ], and Hippo scaffold, Ras GTPase‐activating‐like protein IQGAP1 [IQGAP1], in invasive cutaneous melanoma and breast carcinoma. Furthermore, we demonstrated that PANX1 expression is upregulated in invasive melanoma cell lines and is associated with increased YAP protein levels. Notably, our investigations uncovered a previously unrecognized interaction between endogenous PANX1 and the Hippo scaffold protein IQGAP1 in melanoma cells. Moreover, our findings revealed that IQGAP1 exhibits differential expression in melanoma cells and plays a regulatory role in cellular morphology. Functional studies involving PANX1 knockdown provided compelling evidence that PANX1 modulates YAP protein levels and its cotranscriptional activity in melanoma and breast carcinoma cells. Importantly, our study highlights the potential therapeutic significance of targeting PANX1. Pharmacological inhibition of PANX1 using selective FDA‐approved inhibitors or PANX1 knockdown reduced YAP levels in melanoma cells. Furthermore, our Clariom™ S analysis unveiled key genes implicated in cell proliferation, such as neuroglin1 (NRG1), β‐galactoside binding protein and galectin‐3 (LGALS3), that are affected in PANX1‐deficient cells. In summary, our investigation delves into the intricate interplay between PANX1 and YAP in the context of invasive melanoma, offering valuable insights into potential therapeutic strategies for effective treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNerve Tissue ProteinsConnexinsProtein Serine-Threonine KinasesSkin NeoplasmsHumansSignal TransductionGene Expression Regulation, NeoplasticHippo Signaling PathwayCell Line, TumorYAP-Signaling Proteinsras GTPase-Activating ProteinsAdaptor Proteins, Signal TransducingTranscription FactorsFemaleBreast Neoplasms

Stichwörter der Autor:innen

Hippo pathwayIQGAP1Pannexin 1YAPmalignant melanoma

Substanzen

Nerve Tissue ProteinsPANX1 protein, humanConnexinsProtein Serine-Threonine KinasesIQ motif containing GTPase activating protein 1YAP-Signaling Proteinsras GTPase-Activating ProteinsAdaptor Proteins, Signal TransducingYAP1 protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, USA.
  • Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Canada.
  • Department of Mathematics, Illinois State University, Normal, IL, USA.
  • Ontario College of Pharmacists, Toronto, Canada.
  • Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Canada.

ORCID-Profile: Silvia Penuela

Förderung

  • Intramural NIH HHS
  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Sayedyahossein, S., Huang, K., Zhang, C., Karimi, M., Bahmani, M., O'Donnell, B. L., Wakefield, B., Li, Z., Johnston, D., Leighton, S. E., Huver, M. S., Dagnino, L., Sacks, D. B., & Penuela, S. (2025). Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma. The FEBS Journal. https://doi.org/10.1111/febs.17396

Vancouver

Sayedyahossein S, Huang K, Zhang C, Karimi M, Bahmani M, O'Donnell BL, et al. Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma. The FEBS Journal. 2025. doi:10.1111/febs.17396

BibTeX
@article{Sayedyahossein2025,
  author = {Sayedyahossein, Samar and Huang, Kenneth and Zhang, Christopher and Karimi, Mehdi and Bahmani, Mehrnoosh and O'Donnell, Brooke L and Wakefield, Brent and Li, Zhigang and Johnston, Danielle and Leighton, Stephanie E and Huver, Matthew S and Dagnino, Lina and Sacks, David B and Penuela, Silvia},
  title = {Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.17396}
}
Kostenlos starten →